The development of our proprietary SDMC technology, marketed as Lyphazome technology, occurred over eighteen years of research and began for the treatment of deep scarring from burns. Lyphazome technology is completely natural and metabolized by the body, thereby eliminating the risk often associated with synthetic materials, often used for sustained-release delivery.
Dermazone’s next generation of nanotechnology is our patent pending NLP technology. This technology engineers particle size up or down to accommodate a variety of actives for both rapid or sustained release.
The flexibility of both these technologies allows for either an InSitu or
pre-load encapsulation, depending on the formulation objectives.
Video - Dr. Michael Fountain on Dermazone Technologies (1):
Newly formed enaltus™enters the fast-growing specialty skin care market
enaltus™ emerged as a new, privately held Georgia based company following the acquisition of its prior parent company, Advanced Bio-Technologies, Inc.by Sinclair IS Pharmain December 2011.The new entity offers specialty skin care products to physicians and consumers in the US with a direct marketing and sales organization, and internationally with distributors and partners in over 50 countries around the world.
